363 related articles for article (PubMed ID: 33165773)
1. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
[TBL] [Abstract][Full Text] [Related]
2. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
3. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
4. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Shibata T; Nomura Y; Takada A; Aoki S; Katashima M; Murakami H
J Clin Pharm Ther; 2018 Oct; 43(5):633-639. PubMed ID: 29981285
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Shibata T; Nomura Y; Takada A; Ueno M; Katashima M; Yazawa R; Furihata K
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):304-313. PubMed ID: 29966038
[TBL] [Abstract][Full Text] [Related]
7. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
8. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
10. Roxadustat: First Global Approval.
Dhillon S
Drugs; 2019 Apr; 79(5):563-572. PubMed ID: 30805897
[TBL] [Abstract][Full Text] [Related]
11. The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.
Groenendaal-van de Meent D; den Adel M; Rijnders S; Krebs-Brown A; Kerbusch V; Golor G; Schaddelee M
Clin Ther; 2016 Apr; 38(4):918-28. PubMed ID: 26947173
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
[TBL] [Abstract][Full Text] [Related]
13. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
14. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
15. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
[TBL] [Abstract][Full Text] [Related]
16. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
Mima A; Horii Y
In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease.
Rekić D; Kerbusch-Herben V; Någård M; Chou J; Huang J; Bradley C; Åstrand M; Tannenbaum S; Hamrén B
Clin Pharmacokinet; 2021 Jun; 60(6):759-773. PubMed ID: 33486718
[TBL] [Abstract][Full Text] [Related]
20. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
Groenendaal-van de Meent D; den Adel M; Kerbusch V; van Dijk J; Shibata T; Kato K; Schaddelee M
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):486-501. PubMed ID: 35182045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
